Gabapentin and Pregabalin: Higher Risks Early in Treatment

Gabapentin and Pregabalin: Understanding Risks and Monitoring Needs A recent study led by researchers at University College London (UCL) underscores the importance of clinician vigilance when prescribing gabapentinoids for pain management, highlighting patterns of self-harm risk that require careful patient monitoring throughout treatment. Gabapentinoids, which include the medications gabapentin and pregabalin, are commonly prescribed for conditions such as epilepsy, neuropathic pain and anxiety disorders. Even as these drugs are effective for many patients, concerns have emerged regarding their association with self-harm behaviors. The UCL study analyzed electronic health records from over 10,000 individuals in the UK aged 18 and older who were prescribed gabapentinoids between 2000 and 2020 and had at least one hospital record of self-harm. Researchers found that the risk of self-harm was already elevated in patients before they began taking gabapentinoids, decreased during the treatment period, and then increased again shortly after discontinuation. These findings challenge the assumption of a direct causal link between gabapentinoids and self-harm. Instead, they suggest that the underlying conditions for which gabapentinoids are prescribed—such as chronic pain, epilepsy, and anxiety—may be associated with higher baseline risks of self-harm. The study emphasizes that close monitoring of patients is essential not only during treatment but likewise before initiation and after stopping the medication. Experts note that gabapentinoids should be prescribed with careful consideration of a patient’s full medical and psychiatric history. Clinicians are advised to assess for signs of depression or suicidal ideation before starting treatment and to maintain regular follow-ups throughout the course of therapy. Any changes in mood or behavior should be promptly evaluated. The study does not suggest that gabapentinoids are unsafe when used appropriately. Rather, it reinforces the require for a holistic approach to patient care that includes mental health screening and ongoing support. Patients taking gabapentinoids should be encouraged to discuss any changes in their emotional well-being with their healthcare provider. As prescribing practices for gabapentinoids continue to evolve, ongoing research remains vital to fully understand their long-term effects and optimal use in clinical settings. For now, the evidence supports vigilant monitoring and individualized treatment planning to ensure patient safety.